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Skin toxicities related to epidermal growth factor receptor-
tyrosine kinase inhibitors (EGFR-TKIs) are common, such as acnei-
form eruptions, pruritus, xerosis, and paronychia,1 whereas purpu-
ric drug eruptions with or without leukocytoclastic vasculitis are
rare. Most of the reported cases were treated by discontinuation
of EGFR-TKIs with topical or systemic corticosteroids.2 Herein we
present a case with acantholytic purpuric drug eruptions success-
fully treated with systemic antibiotics without discontinuation of
geﬁtinib. This is also the ﬁrst case with purpuric drug eruptions be-
ing reported to have acantholysis.
An 87-year-old man with hypertension under regular medica-
tion control was diagnosed as having Stage IV nonsmall cell lung
cancer, with a conﬁrmed activatingmutation of EGFR (exon 19 dele-
tion) in February 2015. He began taking oral geﬁtinib 250 mg daily
from March 2, 2015. One month later he developed generalized
pruritus with xerosis which responded well to emollients, topical
corticosteroids, and oral antihistamines. However, after taking geﬁ-
tinib for 3 months, numerous pea-to-bean sized, itching, slightly
tender, scaly, and nonblanchable (purpuric) papules, pustules,
and patches developed on his lower legs in June 2015 (Figure 1A).
A skin biopsy from a representative pustule surrounded by a purpu-
ric rim on the left shin showed epidermal atrophy, hypogranulosis,
subcorneal pustules with focal acantholysis, and perivascular lym-
phocytic inﬁltration with erythrocytes extravasation in the upper
dermis. There was no vessel wall destruction or ﬁbrinoid necrosis
(Figures 1B and 1C). Direct immunoﬂuorescence study was nega-
tive for immunoglobulin (Ig)G, IgA, IgM, complement 3, ﬁbrinogen,
and C1q. Indirect immunoﬂuorescence study did not detect anti-
intercellular substance antibody or antibasement membrane zone
antibody in the serum. On laboratory examinations, a hemogram
showed mild leukocytosis with a normal platelet count of 157 K/
mL. His renal and hepatic functions were within normal limits. A
few days later, the tissue culture from the skin biopsy grew Staph-
ylococcus aureus. The patient was hospitalized on June 26, 2015, for
aggressive wound care with topical chloramphenicol ointment and
parenteral cefazolin. Under the suggestion of his oncologist, he kept
taking geﬁtinib 250 mg daily. Surprisingly, prompt resolution of
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charged from the hospital smoothly on July 3, 2015, after a 7-day
course of parenteral cefazolin.
Except tumor cells, EGFR is also located in basal keratinocytes,
hair follicular outer root sheath, sebocytes, and dermal vessel
smooth muscle cells.3 Three mechanisms contribute to the onset
of EGFR-TKIs skin toxicities: (1) normal basal keratinocyte regener-
ation and differentiation are perturbed by EGFR inhibition, with
resultant impaired stratum corneum,1,4 which contribute to the
development of xerosis and microbial invasion; (2) loss of antimi-
crobial mechanismswith decreased levels of human b defensin, hu-
man cathelicidin, and ribonuclease 7,4 which allows staphylococcal
or other bacterial infections; and (3) increased expression and
release of chemokines and cytokines by EGFR inhibition result in
exaggerated tissue inﬂammation.4 The positive tissue culture and
the prompt response to systemic antibiotics in our patient highlight
the role of staphylococcal infection in this pustular purpuric erup-
tion. Microbial analysis was suggested for EGFR-TKI associated
paronychia.5 However, a tissue culture was rarely done in previous
reported cases with EGFR-TKIs induced purpura or cutaneous
vasculitis.2 We suggest routine microbial analysis for pustular pur-
puric lesions in patients taking EGFR-TKIs.
As for the acantholysis, the patient had negative direct immuno-
ﬂuorescence and indirect immunoﬂuorescence studies, which
exclude autoimmune bullous diseases. In addition to keratinocyte
injury induced shedding, exfoliative toxin A produced by Staphylo-
coccus aureus targets desmoglein 1 and may cause acantholysis.6
Moreover, in a previous report, two out of 10 patients treated
with cetuximab, an EGFR antibody, were noticed to have intraepi-
dermal acantholysis with mild perifolliculitis 4 days and 8 days af-
ter treatment, respectively.7 Neither Candida nor bacteria were
found in culture at the onset of these lesions. Therefore, EGFR inhi-
bition might also contribute to acantholysis. Controversially, EGFR
overactivation could cause loss of cell adhesion in tumor cells and
EGFR inhibition was reported to promote desmosome assembly
and strengthen intercellular adhesion in squamous cell carcinoma
cells.8 However, the effects of EGFR inhibition on intercellular adhe-
sion of keratinocytes, instead of tumor cells, remained unclear.
Further studies may be needed.
Although the mechanism of acantholysis remains unknown, we
present this case to highlight the role of staphylococcal infection,
the need for routine microbial analysis, and systemic antibiotics
may be considered for patients with EGFR-TKI induced pustular
purpuric drug eruption.er Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
Figure 1 Legs of the patient. (A) Umerous scaly and nonblanchable purpuric papules, pustules and patches of pea size on the lower legs. (B) A subcorneal pustule with focal acan-
tholysis, epidermal atrophy, hypogranulosis, and perivascular lymphocytic inﬁltration with erythrocytes extravasations. There was no vessel wall destruction or ﬁbrinoid necrosis
(hematoxylin and eosin, 100). (C) Highlights of acantholysis. Extravasated erythrocytes can be seen in upper dermis (hematoxylin and eosin, 400). (D) Resolution of purpuric
papules and patches with drying up of the pustules a few days after systemic antibiotics.
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